<DOC>
	<DOCNO>NCT02282397</DOCNO>
	<brief_summary>Evaluate addition use real time continuous glucose monitoring ( RT-CGM ) improve glycemic outcome patient use multiple daily injection ( MDI ) self monitor blood glucose ( SMBG ) testing , target glycemic control .</brief_summary>
	<brief_title>Multiple Daily Injections Continuous Glucose Monitoring Diabetes</brief_title>
	<detailed_description>The study design include two cohort treat separately . Phase 1 include two diabetes cohort ( Type 1 diabetes mellitus Type 2 diabetes mellitus ) randomize independently two group , Group 1-CGM Group 2-SMBG . The Group-1 CGM cohort Type 1 diabetes mellitus eligible Phase 2 . Phase 2 include separate independent randomization either MDI therapy ( Group 1a- CGM/MDI ) CSII therapy ( Group 1b-CGM/CSII ) . Additional assessment make evaluate incremental benefit change insulin delivery method MDI CSII patient already use CGM . Cost effectiveness quality life measure two group phase .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Age 25 year old Diagnosis Type 1 diabetes mellitus insulinrequiring Type 2 diabetes mellitus Followed regularly physician diabetes educator Using multiple daily injection stable control diabetes willing wear device pump continuous glucose monitor recent plan use noninsulin injectable hypoglycemic agent Pregnancy plan become pregnant study Medical condition make inappropriate unsafe target A1C &lt; 7 % Renal disease Glomerular Filtration Rate &lt; 45 Extensive skin changes/disease preclude wear sensor normal skin Known allergy medicalgrade adhesives Recent hospitalization emergency room visit 6 month prior screen result primary diagnosis uncontrolled diabetes</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Diabetes Mellitus</keyword>
</DOC>